Targeted Therapies for Rheumatoid Arthritis in Super‐Elderly Society: Insights From FIRST Registry, Japan
International Journal of Rheumatic Diseases · 2025-04 · 28 (4)
DOI: 10.1111/1756-185x.70232 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 24.04.2025. Verfasst von Koshiro Sonomoto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
As the world's most rapidly aging society, Japan has faced significant challenges in the management of rheumatoid arthritis (RA) in elderly patients. Biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) have improved disease control, but concerns remain regarding the risk of infection and malignancy, especially in the elderly population. This review presents real‐world data from FIRST registry, a prospective cohort following a total of 5500 patients over 20 years, and highlights strategies to balance efficacy and safety. Registry shows an increasing age of patients initiating b/tsDMARDs and an increase in comorbidities such as cardiovascular disease, chronic kidney disease, and malignancies. Infection control—including prophylaxis against pneumocystis pneumonia, screening for non‐tuberculous mycobacteria, and vaccination—has been associated with a lower incidence of serious infections. Similarly, a proactive malignancy management strategy that includes computed tomography (CT) screening and multidisciplinary care has been correlated with improved detection of early‐stage cancers and fewer treatment discontinuations due to malignancy. While these findings represent associations rather than direct causal effects, they reflect the evolving landscape of RA management over two decades. Meanwhile, the registry highlights unmet needs, particularly in patients with prior b/tsDMARD exposure, who often experience lower response rates. In addition, while clinical remission rates have improved, functional outcomes remain suboptimal, particularly in older patients. To address these challenges, personalized treatment selection is being explored. By sharing Japan's experience in managing RA in an aging society, this review provides insights into strategies that may be applicable to other aging populations worldwide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
- Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
ORCID-Profile: Koshiro Sonomoto, Yoshiya Tanaka
Zitieren
APA
Sonomoto, K., & Tanaka, Y. (2025). Targeted Therapies for Rheumatoid Arthritis in Super‐Elderly Society: Insights From FIRST Registry, Japan. International Journal of Rheumatic Diseases, 28(4). https://doi.org/10.1111/1756-185x.70232
Vancouver
Sonomoto K, Tanaka Y. Targeted Therapies for Rheumatoid Arthritis in Super‐Elderly Society: Insights From FIRST Registry, Japan. International Journal of Rheumatic Diseases. 2025;28(4). doi:10.1111/1756-185x.70232
BibTeX
@article{Sonomoto2025,
author = {Sonomoto, Koshiro and Tanaka, Yoshiya},
title = {Targeted Therapies for Rheumatoid Arthritis in Super‐Elderly Society: Insights From FIRST Registry, Japan},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
volume = {28},
number = {4},
doi = {10.1111/1756-185x.70232}
}
EUVIMED